JP2010047577A - 1,3,4,5−テトラヒドロ−2h−3−ベンゾアゼピン−2−オン化合物の新規な合成方法、並びにイバブラジン及び薬学的に許容され得る酸とのその付加塩の合成への適用 - Google Patents
1,3,4,5−テトラヒドロ−2h−3−ベンゾアゼピン−2−オン化合物の新規な合成方法、並びにイバブラジン及び薬学的に許容され得る酸とのその付加塩の合成への適用 Download PDFInfo
- Publication number
- JP2010047577A JP2010047577A JP2009220529A JP2009220529A JP2010047577A JP 2010047577 A JP2010047577 A JP 2010047577A JP 2009220529 A JP2009220529 A JP 2009220529A JP 2009220529 A JP2009220529 A JP 2009220529A JP 2010047577 A JP2010047577 A JP 2010047577A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- synthesis
- ivabradine
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(*)CCN(C=CC(C1)=C(C2)C=C(*)C1[U])C2=O Chemical compound *C(*)CCN(C=CC(C1)=C(C2)C=C(*)C1[U])C2=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
【解決手段】式(VI)
で表される化合物を、非酸性溶媒中でパラジウム炭素を触媒とし、水素圧が、1〜220バールで接触水素化反応に付し、次いで、反応混合物を濾過して、1,3,4,5−テトラヒドロ−2H−3−ベンゾアゼピン−2−オン化合物を得る合成方法。[式中、R1及びR2は、同じであるか、又は異なっていてもよく、それぞれ、直鎖若しくは分枝鎖C1〜C8アルコキシ基を表すか、又はそれらを担持する炭素原子とともに、1,3−ジオキサン、1,3−ジオキソラン若しくは1,3−ジオキセパン環を形成する]
【選択図】なし
Description
で示される化合物の合成方法に関するものである。
で示される化合物の合成方法であって、式(VI):
で示される化合物を、非酸性溶媒中で接触水素化反応に付し、次いで、反応混合物を濾過して、式(I)の化合物を得ることを特徴とする合成方法に関するものである。
水素化装置内に、3−[2−(1,3−ジオキソラン−2−イル)エチル]−7,8−ジメトキシ−1,3−ジヒドロ−2H−3−ベンゾアゼピン−2−オン100g、イソプロパノール500ml、及びPd/C10gを導入した。窒素、次いで水素で掃気し、60℃に加熱し、次いで1バールの圧力下、この温度で4時間水素化した。触媒を除去するために、反応混合物を60℃で濾過した。イソプロパノール2x50mlで洗浄した。50℃に冷却し、tert−ブチルメチルエーテル(MTBE)200mlを加えた。20℃に冷却し、次いで、5℃で1時間0分冷蔵した。得られた結晶を5℃で濾取した。一定の重量になるまで乾燥した。期待された化合物を、88%の収率、及び98%より高い化学的純度で得た。
Claims (11)
- 式(VI)の化合物の水素化反応のための触媒が、パラジウム炭素である、請求項1記載の合成方法。
- 式(VI)の化合物の水素化反応の際の水素圧が、1〜220バールである、請求項1又は2のいずれかに記載の合成方法。
- 式(VI)の化合物の水素化反応を、アルコール性溶媒中で実施する、請求項1〜3のいずれか一項に記載の合成方法。
- アルコール性溶媒がエタノール、メタノール又はイソプロパノールである、請求項4記載の合成方法。
- 温度が20〜100℃である、請求項1〜5のいずれか一項に記載の合成方法。
- 温度が40〜80℃である、請求項6記載の合成方法。
- 式(VI)の化合物の特定の場合である、式(VIa)の化合物(式中、R1及びR2が、それらを担持する炭素原子とともに、1,3−ジオキサン、1,3−ジオキソラン又は1,3−ジオキセパン環を形成する)を出発原料として用いる、請求項1〜7のいずれか一項に記載の合成方法。
- R1及びR2が、それらを担持する炭素原子とともに、1,3−ジオキサン、1,3−ジオキソラン又は1,3−ジオキセパン環を形成する、請求項9記載の化合物。
- イバブラジン、薬学的に許容され得るその塩及びその水和物の合成方法であって、式(VI)の化合物を、請求項1記載の方法に従って、式(I)の中間体化合物へと変換し、次いで、式(I)の中間体化合物を、イバブラジンへと変換する合成方法。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0403828 | 2004-04-13 | ||
| FR0403828A FR2868775B1 (fr) | 2004-04-13 | 2004-04-13 | Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005041810A Division JP4515933B2 (ja) | 2004-04-13 | 2005-02-18 | 1,3,4,5−テトラヒドロ−2h−3−ベンゾアゼピン−2−オン化合物の新規な合成方法、並びにイバブラジン及び薬学的に許容され得る酸とのその付加塩の合成への適用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010047577A true JP2010047577A (ja) | 2010-03-04 |
| JP5277130B2 JP5277130B2 (ja) | 2013-08-28 |
Family
ID=34941961
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005041810A Expired - Lifetime JP4515933B2 (ja) | 2004-04-13 | 2005-02-18 | 1,3,4,5−テトラヒドロ−2h−3−ベンゾアゼピン−2−オン化合物の新規な合成方法、並びにイバブラジン及び薬学的に許容され得る酸とのその付加塩の合成への適用 |
| JP2009220529A Expired - Lifetime JP5277130B2 (ja) | 2004-04-13 | 2009-09-25 | 1,3,4,5−テトラヒドロ−2h−3−ベンゾアゼピン−2−オン化合物の新規な合成方法、並びにイバブラジン及び薬学的に許容され得る酸とのその付加塩の合成への適用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005041810A Expired - Lifetime JP4515933B2 (ja) | 2004-04-13 | 2005-02-18 | 1,3,4,5−テトラヒドロ−2h−3−ベンゾアゼピン−2−オン化合物の新規な合成方法、並びにイバブラジン及び薬学的に許容され得る酸とのその付加塩の合成への適用 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US7064200B2 (ja) |
| EP (1) | EP1614687B1 (ja) |
| JP (2) | JP4515933B2 (ja) |
| KR (1) | KR100636499B1 (ja) |
| CN (1) | CN100348585C (ja) |
| AR (1) | AR047707A1 (ja) |
| AT (1) | ATE448221T1 (ja) |
| AU (1) | AU2005200884B2 (ja) |
| BR (1) | BRPI0500590B8 (ja) |
| CA (1) | CA2496712C (ja) |
| CY (1) | CY1109740T1 (ja) |
| DE (1) | DE602005017541D1 (ja) |
| DK (1) | DK1614687T3 (ja) |
| EA (1) | EA007743B1 (ja) |
| EG (1) | EG25619A (ja) |
| ES (1) | ES2336461T3 (ja) |
| FR (1) | FR2868775B1 (ja) |
| GE (1) | GEP20074136B (ja) |
| HR (1) | HRP20100024T1 (ja) |
| MA (1) | MA27598A1 (ja) |
| MX (1) | MXPA05003696A (ja) |
| MY (1) | MY140904A (ja) |
| NO (1) | NO329861B1 (ja) |
| NZ (1) | NZ538328A (ja) |
| PL (1) | PL1614687T3 (ja) |
| PT (1) | PT1614687E (ja) |
| RS (1) | RS51232B (ja) |
| SG (1) | SG116574A1 (ja) |
| SI (1) | SI1614687T1 (ja) |
| UA (1) | UA81773C2 (ja) |
| WO (1) | WO2005111027A1 (ja) |
| ZA (1) | ZA200501468B (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2868775B1 (fr) * | 2004-04-13 | 2008-04-11 | Servier Lab | Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2868777B1 (fr) * | 2004-04-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| GT200500185A (es) * | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| EP2471780B1 (en) | 2007-05-30 | 2014-11-26 | Ind-Swift Laboratories Limited | Crystalline Ivabradine Oxalate Salts and Polymorphs Thereof |
| ES2402765T3 (es) | 2008-12-22 | 2013-05-08 | Krka, D.D., Novo Mesto | Procedimiento de preparación de ivabradina |
| FR2940287B1 (fr) * | 2008-12-24 | 2010-12-24 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
| SI2902384T1 (en) | 2010-02-12 | 2018-03-30 | Krka, D.D., Novo Mesto | The form of ivabradine hydrochloride |
| FR2956401B1 (fr) * | 2010-02-17 | 2012-02-03 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2971507B1 (fr) * | 2011-02-14 | 2013-01-18 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2984320B1 (fr) * | 2011-12-20 | 2013-11-29 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2993561B1 (fr) * | 2012-07-17 | 2014-10-31 | Servier Lab | Procede de synthese enzymatique de la (7s)-1-(3,4-dimethoxy bicyclo[4.2.0]octa-1,3,5-triene 7-yl) n-methyl methanamine, et application a la synthese de l'ivabradine et de ses sels |
| FR3003859B1 (fr) * | 2013-03-26 | 2015-03-13 | Servier Lab | "procede de synthese de derives de la 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin-2-one et application a la synthese de l'ivabradine" |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61282377A (ja) * | 1985-06-01 | 1986-12-12 | ドクトル・カ−ル ト−メ− ゲゼルシヤフト ミツト ベシユレンクテル ハフツンク | 新規ヘテロ芳香族アミン誘導体、これらの化合物を含む医薬製剤 |
| JPH05213890A (ja) * | 1991-09-27 | 1993-08-24 | Adir | 新規(ベンゾシクロアルキル)アルキルアミン化合物 |
| JP4515933B2 (ja) * | 2004-04-13 | 2010-08-04 | レ ラボラトワール セルヴィエ | 1,3,4,5−テトラヒドロ−2h−3−ベンゾアゼピン−2−オン化合物の新規な合成方法、並びにイバブラジン及び薬学的に許容され得る酸とのその付加塩の合成への適用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3119874A1 (de) * | 1981-05-19 | 1982-12-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel" |
| DE3418270A1 (de) * | 1984-05-17 | 1985-11-21 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| EP0204349A3 (de) | 1985-06-01 | 1990-01-03 | Dr. Karl Thomae GmbH | Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| FR2868777B1 (fr) * | 2004-04-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
-
2004
- 2004-04-13 FR FR0403828A patent/FR2868775B1/fr not_active Expired - Fee Related
-
2005
- 2005-02-07 CA CA2496712A patent/CA2496712C/fr not_active Expired - Lifetime
- 2005-02-15 SG SG200500770A patent/SG116574A1/en unknown
- 2005-02-17 US US11/060,043 patent/US7064200B2/en not_active Expired - Lifetime
- 2005-02-18 ZA ZA2005/01468A patent/ZA200501468B/en unknown
- 2005-02-18 MA MA28112A patent/MA27598A1/fr unknown
- 2005-02-18 AU AU2005200884A patent/AU2005200884B2/en not_active Expired
- 2005-02-18 UA UAA200501524A patent/UA81773C2/uk unknown
- 2005-02-18 CN CNB2005100542167A patent/CN100348585C/zh not_active Expired - Lifetime
- 2005-02-18 GE GEAP8647A patent/GEP20074136B/en unknown
- 2005-02-18 MY MYPI20050621A patent/MY140904A/en unknown
- 2005-02-18 BR BRPI0500590A patent/BRPI0500590B8/pt not_active IP Right Cessation
- 2005-02-18 NO NO20050888A patent/NO329861B1/no unknown
- 2005-02-18 AR ARP050100586A patent/AR047707A1/es active IP Right Grant
- 2005-02-18 JP JP2005041810A patent/JP4515933B2/ja not_active Expired - Lifetime
- 2005-02-18 NZ NZ538328A patent/NZ538328A/en not_active IP Right Cessation
- 2005-02-19 KR KR1020050013860A patent/KR100636499B1/ko not_active Expired - Lifetime
- 2005-02-19 EG EG2005020086A patent/EG25619A/xx active
- 2005-02-21 AT AT05290383T patent/ATE448221T1/de active
- 2005-02-21 DE DE602005017541T patent/DE602005017541D1/de not_active Expired - Lifetime
- 2005-02-21 DK DK05290383.8T patent/DK1614687T3/da active
- 2005-02-21 EP EP05290383A patent/EP1614687B1/fr not_active Expired - Lifetime
- 2005-02-21 EA EA200500240A patent/EA007743B1/ru unknown
- 2005-02-21 PL PL05290383T patent/PL1614687T3/pl unknown
- 2005-02-21 PT PT05290383T patent/PT1614687E/pt unknown
- 2005-02-21 ES ES05290383T patent/ES2336461T3/es not_active Expired - Lifetime
- 2005-02-21 WO PCT/FR2005/000396 patent/WO2005111027A1/fr not_active Ceased
- 2005-02-21 SI SI200530864T patent/SI1614687T1/sl unknown
- 2005-02-21 RS RSP-2010/0006A patent/RS51232B/sr unknown
- 2005-04-07 MX MXPA05003696A patent/MXPA05003696A/es active IP Right Grant
-
2009
- 2009-09-25 JP JP2009220529A patent/JP5277130B2/ja not_active Expired - Lifetime
-
2010
- 2010-01-13 HR HR20100024T patent/HRP20100024T1/hr unknown
- 2010-01-19 CY CY20101100053T patent/CY1109740T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61282377A (ja) * | 1985-06-01 | 1986-12-12 | ドクトル・カ−ル ト−メ− ゲゼルシヤフト ミツト ベシユレンクテル ハフツンク | 新規ヘテロ芳香族アミン誘導体、これらの化合物を含む医薬製剤 |
| JPH05213890A (ja) * | 1991-09-27 | 1993-08-24 | Adir | 新規(ベンゾシクロアルキル)アルキルアミン化合物 |
| JP4515933B2 (ja) * | 2004-04-13 | 2010-08-04 | レ ラボラトワール セルヴィエ | 1,3,4,5−テトラヒドロ−2h−3−ベンゾアゼピン−2−オン化合物の新規な合成方法、並びにイバブラジン及び薬学的に許容され得る酸とのその付加塩の合成への適用 |
Non-Patent Citations (2)
| Title |
|---|
| JPN6009002080; 実験化学講座26 有機合成VIII , 1992, 253-257 * |
| JPN6009002081; Protective Group in Organic Synthesis , 1999, 307-322 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5277130B2 (ja) | 1,3,4,5−テトラヒドロ−2h−3−ベンゾアゼピン−2−オン化合物の新規な合成方法、並びにイバブラジン及び薬学的に許容され得る酸とのその付加塩の合成への適用 | |
| JP5276579B2 (ja) | イバブラジン及び薬学的に許容されうる酸とのその付加塩の合成のための新たな方法 | |
| JP4148952B2 (ja) | (1s)−4,5−ジメトキシ−1−(メチルアミノメチル)ベンゾシクロブタン及びその付加塩合成の新規な方法、並びにイバブラジン、及び薬学的に許容され得る酸とのその付加塩の合成への適用 | |
| JP4515934B2 (ja) | イバブラジン及び薬学的に許容し得る酸とのその付加塩の新規合成方法 | |
| WO2011033194A1 (fr) | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable | |
| CN102633720B (zh) | 合成伊伐布雷定和其与药学上可接受的酸的加成盐的方法 | |
| JP5531084B2 (ja) | イバブラジン及びその薬学的に許容され得る酸との付加塩の新規な合成方法 | |
| HK1079777B (en) | Process for the synthesis of 1,3,4,5-tetrahydro-2h-3-benzazepin-2-one compounds, and application thereof | |
| HK1186734B (en) | A process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | |
| HK1145833B (en) | New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120626 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120925 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120928 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121025 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130514 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130520 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5277130 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |